Preterm Twins and Triplets

Simões, Eric A F; King, S. J.; Lehr, Marsha V.; Groothuis, Jessie R.

doi:10.1001/archpedi.1993.02160270065020

Cited by 56 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This association has been observed previously 37 and may be due to differences in provider or parental behavior. Other earlier studies associated multiple birth with a higher risk of RSV pneumonia 38 or RSV hospitalization 39,40 in infants 24–36 wGA. In a study by Simoes et al, 38 all members of a multiple birth set often developed RSV illness concurrently, which was not observed in the current study.…”

Section: Discussionmentioning

confidence: 83%

“…Other earlier studies associated multiple birth with a higher risk of RSV pneumonia 38 or RSV hospitalization 39,40 in infants 24–36 wGA. In a study by Simoes et al, 38 all members of a multiple birth set often developed RSV illness concurrently, which was not observed in the current study. Overall, these results indicate that the 2012 AAP environmental risk factors can identify the infants 32–35 wGA with an elevated risk for severe RSV disease.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis

Ambrose¹,

Anderson

Simões

et al. 2014

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 83%

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis

Ambrose¹,

Anderson

Simões

et al. 2014

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…In a study cohort from Denver between 1993 and 1989 twins and triplets were reported to have a significantly higher risk of sever RSV LRTI and higher rates of RSV related hospitalizations compared to matched singletons [49]. This finding was confirmed by a study on hospitalization rates in preterm infants aged 29 to 36 weeks by Resch , et al in 2005 [15] that revealed multiple gestation being a risk factor for RSV related hospitalization (odds ratio 5,500, CI 95% 1.439- 21.028).…”

Section: Host Related Risk Factors Increasing Severitiy Of Rsv Infectionmentioning

confidence: 99%

Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection

Sommer

Resch²,

Simões³

2011

TOMICROJ

200

183

View full text Add to dashboard Cite

RSV infection is a leading cause of lower respiratory tract infection, especially in High-risk infants with a history of prematurity, bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), neuromusculair impairment, immunodeficiency, and Down syndrome. Host related risk factors that have been identified to be associated with severe RSV related lower respiratory tract infection include young age below 6 months at the beginning of RSV season, multiple birth, male sex, low socioeconomic status and parental education, crowded living conditions, young siblings, maternal smoking and indoor smoke pollution, malnutrition/small for gestational age, family history of atopy or asthma, low cord serum RSV antibody titers, and living at altitude.Risk factors increasing the risk of acquisition of RSV have been identified to be birth before and/or during RSV season, day care attendance, presence of older siblings in school or day-care, and lack of breast feeding. Some of these risk factors are discussed controversially and some of them are found continuously throughout the literature.Given the high cost of RSV prophylaxis, especially for the large population of late preterm infants, algorithms and risk score systems have been published that could identify high-risk infants for treatment with palivizumab out of this gestational age group. Several models reported on an average sensitivity and specificity of 70 percent and, thus, are helpful to identify infants at high risk for severe RSV infection and need for prophylaxis with palivizumab.

show abstract

“…By the age of 2 years, almost all children have an RSV infection and the reinfection is also common [21,22]; moreover, the morbidity and mortality are significantly higher in preterm compared to term infants [23][24][25][26][27][28][29]. Up to now, numerous extrinsic and intrinsic risk factors for RSVassociated hospitalization in early preterm infants have been identified, including: multiple gestations [30], extremely low birth weight and/or gestational age [16,17,31], intrauterine growth restriction [32], chronic lung disease of prematurity [16,17], lack of prenatal care [33], neonatal complications such as intraventricular hemorrhage, necrotizing enterocolitis, mechanical ventilation, bacteremia [34], as well as lower levels of maternal education [33] and low parental socioeconomic status [35,36]. Considering all this and its proven efficacy and safety in preterm children (≤35 weeks of gestation), palivizumab is used for the prevention of severe RSV LRTI in children requiring hospitalization and who are at high risk for the disease [5][6][7][8].…”

Section: Discussionmentioning

confidence: 99%

Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina

Maksić

Heljic

Skokić

et al. 2018

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Prematurity is a risk factor for respiratory syncytial virus (RSV)-associated lower respiratory tract infections (LRTIs), due to immature humoral and cell-mediated immune system in preterm newborns, as well as their incomplete lung development. Palivizumab, a humanized monoclonal antibody against the F glycoprotein of RSV, is licensed for the prevention of severe RSV LRTI in children at high risk for the disease. This study is a part of a larger observational, retrospective-prospective epidemiological study (PONI) conducted at 72 sites across 23 countries in the northern temperate zone. The aim of our non-interventional study was to identify common predictors and factors associated with RSV LRTI hospitalization in non-prophylaxed, moderate-to-late preterm infants, born between 33 weeks and 0 days and 35 weeks and 6 days of gestation, and less than 6 months prior to or during the RSV season in Bosnia and Herzegovina (B&H). A total of 160 moderate-to-late preterm infants were included from four sites in B&H (Sarajevo, Tuzla, Mostar, and Banja Luka). We identified several significant intrinsic and extrinsic factors to be associated with the risk of RSV LRTI hospitalization in the preterm infants, including: comorbidities after birth, shorter hospital stay, admission to NICU/PICU while in the maternity ward, household smoking, low maternal age, breast feeding, number of family members, and history of family/paternal atopy. Overall, our results indicated that the risk of RSV LRTI in preterm newborns can be associated with different environmental and social/cultural factors, and further research is needed to comprehensively evaluate these associations.

show abstract

Preterm Twins and Triplets

Cited by 56 publications

References 13 publications

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis

Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection

Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina

Contact Info

Product

Resources

About